The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Heike A Bischoffferrari - One of the best experts on this subject based on the ideXlab platform.

  • correction of vitamin d status by calcidiol pharmacokinetic profile safety and biochemical effects on bone and Mineral Metabolism of daily and weekly dosage regimens
    Osteoporosis International, 2017
    Co-Authors: Salvatore Minisola, Luisella Cianferotti, Piergianni Biondi, Cristiana Cipriani, Caterina Fossi, F Franceschelli, Francesca Giusti, G Leoncini, Jessica Pepe, Heike A Bischoffferrari
    Abstract:

    Summary Rationale: Calcidiol can be employed to correct vitamin D deficiency. Main results: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and Mineral Metabolism. Significance: Calcidiol supplementation is effective and safe.

  • correction of vitamin d status by calcidiol pharmacokinetic profile safety and biochemical effects on bone and Mineral Metabolism of daily and weekly dosage regimens
    Osteoporosis International, 2017
    Co-Authors: Salvatore Minisola, Luisella Cianferotti, Piergianni Biondi, Cristiana Cipriani, Caterina Fossi, F Franceschelli, Francesca Giusti, G Leoncini, Jessica Pepe, Heike A Bischoffferrari
    Abstract:

    Rationale: Calcidiol can be employed to correct vitamin D deficiency. Main results: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and Mineral Metabolism. Significance: Calcidiol supplementation is effective and safe. The correction of vitamin D status is necessary to maintain an optimal Mineral and skeletal homeostasis. Despite cholecalciferol (vitamin D3) is the most commonly used drug for vitamin D supplementation, the more hydrophilic compound calcidiol (25-hydroxyvitamin D3) can be employed at daily, weekly, and monthly regimens to reach in the short term the target levels of serum 25-hydroxyvitamin D [25(OH)D]. In the administration of different doses of calcidiol pharmacokinetic study (ADDI-D study), the efficacy and safety of daily and weekly dosages of calcidiol were tested. A total of 87 Caucasian, community-dwelling, postmenopausal women, aged 55 years or older, with vitamin D inadequacy (serum 25(OH)D levels <30 ng/ml, with mean 25(OH)D below 20 ng/ml, namely 16.5 ± 7.5 ng/ml) were randomized to receive three different dosages of calcidiol: 20 μg/day, 40 μg/day, and 125 μg/week for 3 months. The attained level of serum 25(OH)D was selected as primary endpoint to assess efficacy, while other parameters of Mineral Metabolism, (serum calcium, parathyroid hormone, phosphate, FGF23, urinary calcium, and markers of bone turnover) were assessed as secondary endpoints to establish safety. In all the three groups, serum 25(OH)D values significantly and promptly rose and plateaued above the 30 ng/ml threshold remaining within safety interval after 14 days of treatment, with similar efficacy for the similar daily and weekly dose regimens. The different dosages were also equally effective in controlling secondary hyperparathyroidism. No significant changes in calcium and phosphate Metabolism and in bone turnover markers were observed for any of the treatments, confirming the safety of this compound. The results of this study demonstrate the short- and mid-term efficacy and safety on core parameters of Mineral Metabolism of different daily or weekly dosages of calcidiol when used to treat vitamin D inadequacy or deficiency in postmenopausal women. Further studies are needed to assess falls as primary outcome of calcidiol supplementation.

Laura S Hillman - One of the best experts on this subject based on the ideXlab platform.

  • percent true calcium absorption Mineral Metabolism and bone mass in children with arthritis effect of supplementation with vitamin d3 and calcium
    Arthritis & Rheumatism, 2008
    Co-Authors: Laura S Hillman, James T Cassidy, John E Hewett, Fungai Chanetsa, Barry Higgins, John David Robertson
    Abstract:

    Objective To assess whether percent true calcium absorption (α) is normal and whether supplementation with placebo, vitamin D3 (2,000 IU/day), calcium (1,000 mg/day), or vitamin D3 plus calcium improves α, Mineral Metabolism, or bone mass accrual in children with arthritis. Methods Eighteen children received all 4 treatments, each for 6 months, in 4 different, randomly assigned orders. Changes in levels of 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH]2D), parathyroid hormone, bone turnover markers, and Minerals and in bone Mineral content were measured. Calcium absorption was determined with a dual stable isotope method using 48Ca administered intravenously and 46Ca administered orally, and measuring 48Ca, 46Ca, and 42Ca in a 24-hour urine specimen by high-resolution inductively coupled plasma mass spectroscopy. Wilcoxon's signed rank test was used both to identify significant change over the treatment period with a given regimen and to compare change with an experimental treatment versus change with placebo. Results Percent true calcium absorption was in the lower-normal range and did not differ by treatment (mean ± SD 28.3 ± 20.2% with placebo, 26.1 ± 12.1% with calcium, 19.2 ± 11.7% with vitamin D3, and 27.1 ± 16.5% with vitamin D3 plus calcium). With vitamin D3 and vitamin D3 plus calcium treatment, 25(OH)D levels were increased and 1,25(OH)2D levels were maintained. Serum calcium levels were increased only with vitamin D3 and vitamin D3 plus calcium treatment. Levels of bone turnover markers and increases in bone Mineral content did not differ by treatment. Conclusion The findings of this study indicate that percent true calcium absorption is low-normal in children with arthritis. Vitamin D3 at 2,000 IU/day increases serum 25(OH)D and calcium levels but does not improve bone mass accretion. Calcium at 1,000 mg/day also failed to improve bone mass.

  • percent true calcium absorption Mineral Metabolism and bone Mineralization in children with cystic fibrosis effect of supplementation with vitamin d and calcium
    Pediatric Pulmonology, 2008
    Co-Authors: Laura S Hillman, James T Cassidy, Mihaela F Popescu, John E Hewett, Joseph Kyger, David J Robertson
    Abstract:

    Objective To assess whether percent true calcium absorption (α) is normal in children with cystic fibrosis (CF) and to assess whether supplementation with 2,000 IU vitamin D3, 1 g calcium, or both will alter α, Mineral Metabolism, and/or bone mass in children with CF. Study Design Fifteen children ages 7–13 were randomly assigned to one of four different orders to receive all four 6-month treatments including placebos. Change in 25-hydroxyvitamin D (25-OHD), 1,25-dihydroxyvitamin D (1,25(OH)2D), PTH, bone turnover markers, and Minerals after 6 months, and bone Mineral content (Hologic 1000W) after 9 months was measured. α was measured by a dual stable isotope method using 48Ca intravenously and 46Ca orally and measuring 48Ca, 46Ca, and 42Ca in a 24-hr urine using High Resolution Inductively Coupled Mass Spectroscopy (HR-ICP-MS). Analysis used Wilcoxon Sign Ranks. Results α was in the normal range and did not differ by treatment (P 35 ± 10%, Ca 38 ± 23%, D 36 ± 11%, D + Ca 46 ± 21%). One gram calcium did not increase serum or urine calcium. Two thousand IU D3 did not increase 25-OHD or change 1,25(OH)2D. Serum and urine Minerals, markers of bone turnover and bone Mineral gains did not differ by treatment. Conclusions α is normal in children with CF. One gram calcium and/or 2,000 IU D3 does not change α or increase 25-OHD, serum calcium, or Mineralization. Longer trials of a significantly higher dose of vitamin D3 shown to increase serum 25-OHD are needed to assess effects on Mineral Metabolism and bone mass accrual. However, study of therapeutic options other than calcium and vitamin D should be encouraged. Pediatr Pulmonol. 2008; 43:772–780. © 2008 Wiley-Liss, Inc.

Salvatore Minisola - One of the best experts on this subject based on the ideXlab platform.

  • correction of vitamin d status by calcidiol pharmacokinetic profile safety and biochemical effects on bone and Mineral Metabolism of daily and weekly dosage regimens
    Osteoporosis International, 2017
    Co-Authors: Salvatore Minisola, Luisella Cianferotti, Piergianni Biondi, Cristiana Cipriani, Caterina Fossi, F Franceschelli, Francesca Giusti, G Leoncini, Jessica Pepe, Heike A Bischoffferrari
    Abstract:

    Rationale: Calcidiol can be employed to correct vitamin D deficiency. Main results: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and Mineral Metabolism. Significance: Calcidiol supplementation is effective and safe. The correction of vitamin D status is necessary to maintain an optimal Mineral and skeletal homeostasis. Despite cholecalciferol (vitamin D3) is the most commonly used drug for vitamin D supplementation, the more hydrophilic compound calcidiol (25-hydroxyvitamin D3) can be employed at daily, weekly, and monthly regimens to reach in the short term the target levels of serum 25-hydroxyvitamin D [25(OH)D]. In the administration of different doses of calcidiol pharmacokinetic study (ADDI-D study), the efficacy and safety of daily and weekly dosages of calcidiol were tested. A total of 87 Caucasian, community-dwelling, postmenopausal women, aged 55 years or older, with vitamin D inadequacy (serum 25(OH)D levels <30 ng/ml, with mean 25(OH)D below 20 ng/ml, namely 16.5 ± 7.5 ng/ml) were randomized to receive three different dosages of calcidiol: 20 μg/day, 40 μg/day, and 125 μg/week for 3 months. The attained level of serum 25(OH)D was selected as primary endpoint to assess efficacy, while other parameters of Mineral Metabolism, (serum calcium, parathyroid hormone, phosphate, FGF23, urinary calcium, and markers of bone turnover) were assessed as secondary endpoints to establish safety. In all the three groups, serum 25(OH)D values significantly and promptly rose and plateaued above the 30 ng/ml threshold remaining within safety interval after 14 days of treatment, with similar efficacy for the similar daily and weekly dose regimens. The different dosages were also equally effective in controlling secondary hyperparathyroidism. No significant changes in calcium and phosphate Metabolism and in bone turnover markers were observed for any of the treatments, confirming the safety of this compound. The results of this study demonstrate the short- and mid-term efficacy and safety on core parameters of Mineral Metabolism of different daily or weekly dosages of calcidiol when used to treat vitamin D inadequacy or deficiency in postmenopausal women. Further studies are needed to assess falls as primary outcome of calcidiol supplementation.

  • correction of vitamin d status by calcidiol pharmacokinetic profile safety and biochemical effects on bone and Mineral Metabolism of daily and weekly dosage regimens
    Osteoporosis International, 2017
    Co-Authors: Salvatore Minisola, Luisella Cianferotti, Piergianni Biondi, Cristiana Cipriani, Caterina Fossi, F Franceschelli, Francesca Giusti, G Leoncini, Jessica Pepe, Heike A Bischoffferrari
    Abstract:

    Summary Rationale: Calcidiol can be employed to correct vitamin D deficiency. Main results: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and Mineral Metabolism. Significance: Calcidiol supplementation is effective and safe.

  • guidelines on prevention and treatment of vitamin d deficiency italian society for osteoporosis Mineral Metabolism and bone diseases siommms
    Reumatismo, 2011
    Co-Authors: Silvano Adami, Elisabetta Romagnoli, Vincenzo Carnevale, Alfredo Scillitani, Andrea Giusti, Maurizio Rossini, Davide Gatti, R Nuti, Salvatore Minisola
    Abstract:

    The Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS) has elaborated the following guidelines about the definition, prevention and treatment of inadequate vitamin D status. The highlights are presented here.

  • guidelines on prevention and treatment of vitamin d deficiency italian society for osteoporosis Mineral Metabolism and bone diseases siommms
    Reumatismo, 2011
    Co-Authors: Silvano Adami, Elisabetta Romagnoli, Vincenzo Carnevale, Alfredo Scillitani, Andrea Giusti, Maurizio Rossini, Davide Gatti, R Nuti, Salvatore Minisola
    Abstract:

    The Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS) has elaborated the following guidelines about the definition, prevention and treatment of inadequate vitamin D status. The highlights are presented here. Daily vitamin D allowance ranges from 1,500 IU (healthy adults) to 2,300 IU (elderly with low calcium intake). Since the average Italian diet includes around 300 IU/day, subjects with no effective sun exposure should be supplemented with 1,200-2,000 IU vitamin D per day. The serum 25-hydroxy-vitamin D [25(OH)D] levels represents the most accurate way to assess vitamin D repletion, even though there are still no standardized assay methods. Conditions of “deficiency” and “insufficiency” are defined by the following ranges of 25(OH)D levels: less than 20 ng/ml and 20-30 ng/ml, respectively. In Italy, approximately 50% of young healthy subjects have vitamin D insufficiency during the winter months. The prevalence of deficiency increases with ageing, affecting almost all elderly subjects not on vitamin D supplements. When a condition of deficiency has been identified, a cumulative dose of 300,000-1,000,000 IU, over 1-4 weeks is recommended. In subjects recently treated for deficiency-insufficiency, a maintenance dose of 800-2,000 IU/day (or weekly equivalent) is recommended. In patients on daily doses over 1,000 IU, 25(OH)D levels should be checked regularly (e.g. once every two years). The highest tolerated daily dose has been identified as 4,000 IU/day. Vitamin D supplementation should be carefully monitored in patients at higher risk of vitamin D intoxication (granulomatosis) or with primary hyperparathyroidism. In pregnant women, vitamin D supplements should be given as in non-pregnant women, but bolus administration (i.e.: single dose >25,000 IU) should be avoided.

John David Robertson - One of the best experts on this subject based on the ideXlab platform.

  • percent true calcium absorption Mineral Metabolism and bone mass in children with arthritis effect of supplementation with vitamin d3 and calcium
    Arthritis & Rheumatism, 2008
    Co-Authors: Laura S Hillman, James T Cassidy, John E Hewett, Fungai Chanetsa, Barry Higgins, John David Robertson
    Abstract:

    Objective To assess whether percent true calcium absorption (α) is normal and whether supplementation with placebo, vitamin D3 (2,000 IU/day), calcium (1,000 mg/day), or vitamin D3 plus calcium improves α, Mineral Metabolism, or bone mass accrual in children with arthritis. Methods Eighteen children received all 4 treatments, each for 6 months, in 4 different, randomly assigned orders. Changes in levels of 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH]2D), parathyroid hormone, bone turnover markers, and Minerals and in bone Mineral content were measured. Calcium absorption was determined with a dual stable isotope method using 48Ca administered intravenously and 46Ca administered orally, and measuring 48Ca, 46Ca, and 42Ca in a 24-hour urine specimen by high-resolution inductively coupled plasma mass spectroscopy. Wilcoxon's signed rank test was used both to identify significant change over the treatment period with a given regimen and to compare change with an experimental treatment versus change with placebo. Results Percent true calcium absorption was in the lower-normal range and did not differ by treatment (mean ± SD 28.3 ± 20.2% with placebo, 26.1 ± 12.1% with calcium, 19.2 ± 11.7% with vitamin D3, and 27.1 ± 16.5% with vitamin D3 plus calcium). With vitamin D3 and vitamin D3 plus calcium treatment, 25(OH)D levels were increased and 1,25(OH)2D levels were maintained. Serum calcium levels were increased only with vitamin D3 and vitamin D3 plus calcium treatment. Levels of bone turnover markers and increases in bone Mineral content did not differ by treatment. Conclusion The findings of this study indicate that percent true calcium absorption is low-normal in children with arthritis. Vitamin D3 at 2,000 IU/day increases serum 25(OH)D and calcium levels but does not improve bone mass accretion. Calcium at 1,000 mg/day also failed to improve bone mass.

Dirk Kuypers - One of the best experts on this subject based on the ideXlab platform.

  • natural history of Mineral Metabolism bone turnover and bone Mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol
    Nephrology Dialysis Transplantation, 2020
    Co-Authors: Pieter Evenepoel, Kathleen Claes, Bjorn Meijers, Michael R Laurent, Bert Bammens, Maarten Naesens, Ben Sprangers, Etienne Cavalier, Dirk Kuypers
    Abstract:

    The skeletal effects of renal transplantation are not completely understood, especially in patients managed with a steroid minimization immunosuppressive protocol and long term. We enrolled 69 adult transplant recipients (39 males; ages 51.1 ± 12.2 years), free of antiresorptive therapy and managed with a steroid minimization immunosuppressive protocol, into a 5-year prospective observational study to evaluate changes in areal bone Mineral density (aBMD), Mineral Metabolism and bone remodelling. Dual energy X-ray absorptiometry, laboratory parameters of Mineral Metabolism (including parathyroid hormone, sclerostin and fibroblast growth factor 23) and non-renal cleared bone turnover markers (BTMs) (bone-specific alkaline phosphatase, trimeric N-terminal propeptide and tartrate-resistant acid phosphatase 5b) were assessed at baseline and 1 and 5 years post-transplantation. The mean cumulative methylprednisolone exposure at 1 and 5 years amounted to 2.5 ± 0.8 and 5.8 ± 3.3 g, respectively. Overall, bone remodelling activity decreased after transplantation. Post-transplant aBMD changes were minimal and were significant only in the ultradistal radius during the first post-operative year {median -2.2% [interquartile range (IQR) -5.9-1.2] decline, P = 0.01} and in the lumbar spine between Years 1 and 5 [median 1.6% (IQR -3.2-7.0) increase, P = 0.009]. BTMs, as opposed to Mineral Metabolism parameters and cumulative corticosteroid exposure, associated with aBMD changes, both in the early and late post-transplant period. Most notably, aBMD changes inversely associated with bone remodelling changes. In summary, in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol, BMD changes are limited, highly variable and related to remodelling activity rather than corticosteroid exposure.